Targeting the tumor niche to treat cancer.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol (2011) 1.94

Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol (2007) 1.58

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood (2005) 1.33

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood (2012) 1.19

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol (2013) 1.13

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer (2008) 1.01

Radioimmunoconjugates for the treatment of cancer. Semin Oncol (2014) 0.99

Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol (2013) 0.94

CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Leuk Lymphoma (1996) 0.93

The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest (2008) 0.92

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proc Natl Acad Sci U S A (2015) 0.83

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer (2014) 0.80